EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC-ND 4.0

Clinical Trials in Cardiogenic Shock

Anju Bhardwaj, Sahoor Khan, Shashank S Sinha, Preethi Pirlamarla, Rajiv Sankaranarayanan, Alexander Hajduczok, Holger Thiele, Navin K Kapur

JACC: Advances · 2023-12 · 2 (10) · 100708

DOI: 10.1016/j.jacadv.2023.100708 ↗

Kurz gefasst

Editorial in der Zeitschrift JACC: Advances, 2023-12. Verfasst von Anju Bhardwaj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Cardiopulmonary Therapies and Transplantation, McGovern Medical School, University of Texas-Houston, Houston, Texas, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C ardiogenic shock (CS) is a heterogeneous clinical syndrome precipitated by a primary cardiac pathology and marked by critical end-organ hypoperfusion leading to multiorgan failure and death. 1 Despite the numerous advances in percutaneous revascularization techniques and temporary mechanical circulatory support (MCS), inhospital mortality due to CS remains unacceptably high.Given this, the need for appropriately designed and adequately powered randomized controlled trials (RCTs) within this space is dire.However, most existing studies are plagued by inadequate sample sizes, variable definitions of CS, acute myocardial infarction-related CS (AMI-CS)-focused data, nonprotocolized timing of mechanical hemodynamic support, and inconsistent clinical endpoints studied.Furthermore, RCTs in CS are fraught with various methodological, ethical, and operational challenges and are difficult to enroll in.Within this perspective, we identify challenges associated with the design and execution of CS RCTs and suggest solutions for future development of high-quality multicenter clinical trials to advance the field (Figure 1).

Schlagwörter

Stichwörter der Autor:innen

cardiogenic shockrandomized clinical trials

Autor:innen und Institutionen

  • Department of Advanced Cardiopulmonary Therapies and Transplantation, McGovern Medical School, University of Texas-Houston, Houston, Texas, USA.
  • Division of Cardiology, Department of Interventional Cardiology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.
  • Division of Cardiology, INOVA, Church Falls, Virginia, USA.
  • Division of Cardiology, Icahn Mount Sinai School of Medicine, New York, New York, USA.
  • Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
  • Division of Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

Zitieren

APA

Bhardwaj, A., Khan, S., Sinha, S. S., Pirlamarla, P., Sankaranarayanan, R., Hajduczok, A., Thiele, H., & Kapur, N. K. (2023). Clinical Trials in Cardiogenic Shock. JACC: Advances, 2(10), 100708. https://doi.org/10.1016/j.jacadv.2023.100708

Vancouver

Bhardwaj A, Khan S, Sinha SS, Pirlamarla P, Sankaranarayanan R, Hajduczok A, et al. Clinical Trials in Cardiogenic Shock. JACC: Advances. 2023;2(10):100708. doi:10.1016/j.jacadv.2023.100708

BibTeX
@article{Bhardwaj2023,
  author = {Bhardwaj, Anju and Khan, Sahoor and Sinha, Shashank S and Pirlamarla, Preethi and Sankaranarayanan, Rajiv and Hajduczok, Alexander and Thiele, Holger and Kapur, Navin K},
  title = {Clinical Trials in Cardiogenic Shock},
  journal = {JACC: Advances},
  year = {2023},
  volume = {2},
  number = {10},
  pages = {100708},
  doi = {10.1016/j.jacadv.2023.100708}
}
Kostenlos starten →